7MO Oritinib (SH-1028) a third-generation EGFR tyrosine kinase inhibitor in locally advanced or metastatic NSCLC patients with positive EGFR T790M: Results of a single-arm phase II trial.
Saved in:
| Title: | 7MO Oritinib (SH-1028) a third-generation EGFR tyrosine kinase inhibitor in locally advanced or metastatic NSCLC patients with positive EGFR T790M: Results of a single-arm phase II trial. |
|---|---|
| Authors: | Zhou, C.1 (AUTHOR), Xiong, A.1 (AUTHOR), Zhao, J.2 (AUTHOR), Li, W.3 (AUTHOR), Bi, M.3 (AUTHOR), Chen, J.4 (AUTHOR), Li, K.4 (AUTHOR), Miao, L.5 (AUTHOR), Mao, Y.6 (AUTHOR), Wang, D.7 (AUTHOR), Liu, C.8 (AUTHOR), Zeng, A.9 (AUTHOR), Li, R.10 (AUTHOR), Pan, Y.11 (AUTHOR), Hu, Y.12 (AUTHOR), Zhang, X.13 (AUTHOR), Niu, H.14 (AUTHOR), Du, Y.15 (AUTHOR), Sun, Y.16 (AUTHOR), Liu, Z.17 (AUTHOR) |
| Source: | Annals of Oncology. 2022 Supplement 2, Vol. 33, pS31-S31. 1p. |
| Database: | Academic Search Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 155963102 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: 7MO Oritinib (SH-1028) a third-generation EGFR tyrosine kinase inhibitor in locally advanced or metastatic NSCLC patients with positive EGFR T790M: Results of a single-arm phase II trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Zhou%2C+C%2E%22">Zhou, C.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Xiong%2C+A%2E%22">Xiong, A.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Zhao%2C+J%2E%22">Zhao, J.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Li%2C+W%2E%22">Li, W.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bi%2C+M%2E%22">Bi, M.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Chen%2C+J%2E%22">Chen, J.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Li%2C+K%2E%22">Li, K.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Miao%2C+L%2E%22">Miao, L.</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mao%2C+Y%2E%22">Mao, Y.</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Wang%2C+D%2E%22">Wang, D.</searchLink><relatesTo>7</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Liu%2C+C%2E%22">Liu, C.</searchLink><relatesTo>8</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Zeng%2C+A%2E%22">Zeng, A.</searchLink><relatesTo>9</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Li%2C+R%2E%22">Li, R.</searchLink><relatesTo>10</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Pan%2C+Y%2E%22">Pan, Y.</searchLink><relatesTo>11</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hu%2C+Y%2E%22">Hu, Y.</searchLink><relatesTo>12</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Zhang%2C+X%2E%22">Zhang, X.</searchLink><relatesTo>13</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Niu%2C+H%2E%22">Niu, H.</searchLink><relatesTo>14</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Du%2C+Y%2E%22">Du, Y.</searchLink><relatesTo>15</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Sun%2C+Y%2E%22">Sun, Y.</searchLink><relatesTo>16</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Liu%2C+Z%2E%22">Liu, Z.</searchLink><relatesTo>17</relatesTo> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Annals+of+Oncology%22">Annals of Oncology</searchLink>. 2022 Supplement 2, Vol. 33, pS31-S31. 1p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=155963102 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.annonc.2022.02.016 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 1 StartPage: S31 Titles: – TitleFull: 7MO Oritinib (SH-1028) a third-generation EGFR tyrosine kinase inhibitor in locally advanced or metastatic NSCLC patients with positive EGFR T790M: Results of a single-arm phase II trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Zhou, C. – PersonEntity: Name: NameFull: Xiong, A. – PersonEntity: Name: NameFull: Zhao, J. – PersonEntity: Name: NameFull: Li, W. – PersonEntity: Name: NameFull: Bi, M. – PersonEntity: Name: NameFull: Chen, J. – PersonEntity: Name: NameFull: Li, K. – PersonEntity: Name: NameFull: Miao, L. – PersonEntity: Name: NameFull: Mao, Y. – PersonEntity: Name: NameFull: Wang, D. – PersonEntity: Name: NameFull: Liu, C. – PersonEntity: Name: NameFull: Zeng, A. – PersonEntity: Name: NameFull: Li, R. – PersonEntity: Name: NameFull: Pan, Y. – PersonEntity: Name: NameFull: Hu, Y. – PersonEntity: Name: NameFull: Zhang, X. – PersonEntity: Name: NameFull: Niu, H. – PersonEntity: Name: NameFull: Du, Y. – PersonEntity: Name: NameFull: Sun, Y. – PersonEntity: Name: NameFull: Liu, Z. IsPartOfRelationships: – BibEntity: Dates: – D: 02 M: 04 Text: 2022 Supplement 2 Type: published Y: 2022 Identifiers: – Type: issn-print Value: 09237534 Numbering: – Type: volume Value: 33 Titles: – TitleFull: Annals of Oncology Type: main |
| ResultId | 1 |
